Sagimet Biosciences Inc. Research and Development Expense
Sagimet Biosciences Inc. (SGMT) reported Research and Development Expense of $11.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Sagimet Biosciences Inc. research and development expense for the quarter ending 2026-06-30 was $11.54M, a 59.15% increase year-over-year.
- Sagimet Biosciences Inc. research and development expense for the quarter ending 2026-03-31 was $7.00M, a 54.41% decline year-over-year.
- Sagimet Biosciences Inc. research and development expense for the quarter ending 2025-12-31 was $6.73M, a 52.63% decline year-over-year.
- Sagimet Biosciences Inc. research and development expense for the quarter ending 2025-09-30 was $9.73M, a 23.10% decline year-over-year.
- Sagimet Biosciences Inc. research and development expense for fiscal 2025 was $39.05M, a 1.59% increase from fiscal 2024.
- Sagimet Biosciences Inc. research and development expense for fiscal 2024 was $38.44M, a 94.39% increase from fiscal 2023.
- Sagimet Biosciences Inc. research and development expense for fiscal 2023 was $19.78M, a 20.63% decline from fiscal 2022.
- Sagimet Biosciences Inc. research and development expense for fiscal 2022 was $24.92M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.54M 10-Q · filed 2026-08-11 | $18.53M 10-Q · filed 2026-08-11 | $25.26M derived: sum of 3 quarters · filed 2026-08-11 | $34.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $7.00M 10-Q · filed 2026-05-12 | $13.73M derived: sum of 2 quarters · filed 2026-05-12 | $23.46M derived: sum of 3 quarters · filed 2026-05-12 | $30.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $6.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $16.46M derived: sum of 2 quarters · filed 2026-03-11 | $23.71M derived: sum of 3 quarters · filed 2026-08-11 | $39.05M 10-K · filed 2026-03-11 |
| 2025-09-30 | $9.73M 10-Q · filed 2025-11-13 | $16.98M derived: sum of 2 quarters · filed 2026-08-11 | $32.32M 10-Q · filed 2025-11-13 | $46.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $7.25M 10-Q · filed 2026-08-11 | $22.59M 10-Q · filed 2026-08-11 | $36.81M derived: sum of 3 quarters · filed 2026-08-11 | $49.46M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $15.34M 10-Q · filed 2026-05-12 | $29.56M derived: sum of 2 quarters · filed 2026-05-12 | $42.21M derived: sum of 3 quarters · filed 2026-05-12 | $48.52M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $14.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $26.87M derived: sum of 2 quarters · filed 2026-03-11 | $33.18M derived: sum of 3 quarters · filed 2026-03-11 | $38.44M 10-K · filed 2026-03-11 |
| 2024-09-30 | $12.65M 10-Q · filed 2025-11-13 | $18.97M derived: sum of 2 quarters · filed 2025-11-13 | $24.23M 10-Q · filed 2025-11-13 | $29.88M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $6.31M 10-Q · filed 2025-08-13 | $11.57M 10-Q · filed 2025-08-13 | $17.23M derived: sum of 3 quarters · filed 2025-08-13 | $22.19M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $5.26M 10-Q · filed 2025-05-08 | $10.92M derived: sum of 2 quarters · filed 2025-05-08 | $15.88M derived: sum of 3 quarters · filed 2025-05-08 | $20.55M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $5.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $10.61M derived: sum of 2 quarters · filed 2025-03-12 | $15.29M derived: sum of 3 quarters · filed 2025-03-12 | $19.78M 10-K · filed 2025-03-12 |
| 2023-09-30 | $4.96M 10-Q · filed 2024-11-14 | $9.63M derived: sum of 2 quarters · filed 2024-11-14 | $14.12M 10-Q · filed 2024-11-14 | $19.97M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $4.68M 10-Q · filed 2024-08-14 | $9.16M 10-Q · filed 2024-08-14 | $15.01M derived: sum of 3 quarters · filed 2024-08-14 | $21.85M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $4.49M 10-Q · filed 2024-05-15 | $10.33M derived: sum of 2 quarters · filed 2024-05-15 | $17.17M derived: sum of 3 quarters · filed 2024-05-15 | $23.54M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $12.69M derived: sum of 2 quarters · filed 2024-03-25 | $19.06M derived: sum of 3 quarters · filed 2024-03-25 | $24.92M 10-K · filed 2024-03-25 |
| 2022-09-30 | $6.84M 10-Q · filed 2023-11-13 | $13.21M derived: sum of 2 quarters · filed 2023-11-13 | $19.07M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $6.37M 10-Q · filed 2023-08-21 | $12.23M 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |